From Reuters:
https://www.reuters.com/enterprise/healthcare-pharmaceuticals/moderna-merck-vaccine-combo-cut-melanoma-recurrence-by-44-study-2022-12-13/
In a mid-stage trial, seems just like the mRNA most cancers vaccine from Moderna coupled with Merck’s immuntherapy drug reduce recurrence & demise by 44%:
Paul Burton, Moderna’s chief medical officer, stated in a separate interview the mix “has the capability to be a brand new paradigm within the remedy of most cancers.”
The ongoing research concerned 157 sufferers with stage III/IV melanoma whose tumors have been surgically eliminated earlier than being handled with the drug/vaccine combo or Keytruda alone with the purpose of delaying illness recurrence.
The mixture was typically secure and confirmed a statistically important profit in contrast with Keytruda alone after a yr of remedy. Critical drug-related unwanted effects occurred in 14.4% of sufferers who acquired the drug-vaccine mixture in contrast with 10% with Keytruda alone.
